GlycoMimetics, Inc. ( GLYC ) stock is moving higher Monday after its chief medical officer disclosed the purchase of company stock.

The Details: On Tuesday, the chief medical officer Edwin Rock disclosed in a Form4 that he bought 305,000 shares of the company.

Rock purchased the shares at an average price of 26 cents.

How To Buy GlycoMimetics Stock

An investor can make a few decisions when deciding whether a stock is a good buy. In addition to valuation metrics and price action which you can find on Benzinga's quote pages – like GlycoMimetics ( GLYC )‘s page for example – there are factors like whether or not a company pays a dividend or buys a large portion of its stock each quarter.

These are known as capital allocation programs. GlycoMimetics ( GLYC ) does not pay a dividend, but obviously has a few ways it can return value to shareholders. Feel free to search Benzinga's dividend calendar for the next company that is due to pay a dividend and determine what kind of yield you can earn for holding a share of the company.

For example, if you're looking to earn an annualized return of 21.91%, you'll need to buy a share of Simplify Exchange Traded Funds Simplify Propel Opportunities ETF by the Jun. 25, 2024. Once done, you can expect to receive a nominal payout of $1.25 on Jun. 28, 2024.

Buyback programs are obviously different and highly variable. A company can approve a buyback program and purchase shares as it sees fit over the course of time in which the buyback was authorized. Looking through the latest news on GlycoMimetics ( GLYC ) will often yield whether or not the company has approved a buyback program recently. Buyback programs usually serve as a support for share prices, serving as a backstop for demand.

Related Link: 5 Biotech Stocks With Key Catalysts This Week: Merck, Intellia, Verona, And More

GLYC Price Action: At the time of publication, GlycoMimetics ( GLYC ) shares is trading 20% higher at 32 cents, according to data from Benzinga Pro.

Image: 8676549 from Pixabay.